Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center ...

"LUT014 0.1% gel provides statistically significant benefit over placebo gel for the treatment of acneiform rash associated with cetuximab (Erbitux) or panitumumab (Vectibix) therapy for patients ...

Anti-EGFR therapies, such as cetuximab and panitumumab, are a cornerstone of treatment for many cancers, including colorectal cancer. However, they often cause an acneiform rash that frequently ...

Anti-EGFR therapies, such as cetuximab and panitumumab, are a cornerstone of treatment for many cancers, including colorectal cancer. However, they often cause an acneiform rash that frequently ...

Lumakras plus Vectibix showed improved overall survival and response rates in KRAS G12C metastatic colorectal cancer, though ...

Panitumumab, the first fully human antibody that targets the EGFR, significantly improved the progression-free survival of patients with metastatic colorectal cancer (CRC) in a phase III trial.

Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Vectibix (panitumumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets ...

Anti-EGFR therapies, such as cetuximab and panitumumab, are a cornerstone of treatment for many cancers, including colorectal cancer. However, they often cause an acneiform rash that frequently ...

Anti-EGFR therapies, such as cetuximab and panitumumab, are a cornerstone of treatment for many cancers, including colorectal cancer. However, they often cause an acneiform rash that frequently ...